

# A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

NCT06725381

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
<b>Enrollment</b>	138 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Subjects aged 18-75 years at the time of signing the informed consent form
  - Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumors .
  - Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1.
  - Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1.
  - Subjects who are assessed by the investigator to have an expected survival of e 3 months.
- ... and 6 more (see full listing online)

### Exclusion (16)

- Subjects with known active or untreated central nervous system (CNS) metastases.
  - Subjects with other malignant tumors within 3 years prior to the first dose.
  - Subjects with history of major cardiovascular, cerebrovascular, or thromboembolic disease.
  - Subjects with known active pulmonary tuberculosis.
  - Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C.
- ... and 11 more (see full listing online)

## Locations (15 total)

---

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China  
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China  
Hubei Cancer Hospital, Wuhan, Hubei, China  
... and 12 more locations